This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Establishing a 'Proof of Principle'

Samuel Hellman, MD

JAMA. 1994;271(12):945-946.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Often in medical investigation there is a period of early enthusiasm when the initial discovery is appreciated and the possible applications and implications are considered. When the discovery is a new therapeutic modality, this initial period of great expectation is followed by a greater understanding of both the toxicity of the agent as well as the limitations of the treatment efficacy, leading to some disillusionment. It is only with time, experience, and careful reporting of the complete experience that the new therapy can be evaluated and its importance determined.

This has surely been the case with interleukin 2 (IL-2) treatment for cancer. Early reports of the use of IL-2 published by the National Cancer Institute surgery group led by Dr Rosenberg^1,2 generated considerable interest. Much was written in both the medical literature and the lay press following publication of some of the initial responses observed with IL-2 treatment for . . . [Full Text PDF of this Article]

Author Affiliations
From the Department of Radiation and Cellular Oncology, The University of Chicago (III).

Footnotes
Reprint requests to Department of Radiation and Cellular Oncology, The University of Chicago, 5841 S Maryland Ave, MC 0011, Chicago, IL 60637 (Dr Hellman).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?